^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rilvegostomig (AZD2936)

    i
    Other names: AZD2936, AZD-2936, AZD 2936
    Company:
    AstraZeneca, Compugen, Xoma
    Drug class:
    PD1 inhibitor, TIGIT inhibitor
    Related drugs:
    18d
    Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Jeeyun Lee | N=50 --> 100
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • CLDN18.2 positive
    |
    Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    20d
    ARTEMIDE-Lung03: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (clinicaltrials.gov)
    P3, N=878, Recruiting, AstraZeneca | Trial completion date: Mar 2030 --> Nov 2030 | Trial primary completion date: May 2029 --> Nov 2030
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • EGFR L861Q • ROS1 rearrangement • EGFR G719X • EGFR S768I • EGFR L858R + EGFR exon 19 deletion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)
    23d
    MST01-AZN-05: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC (clinicaltrials.gov)
    P1, N=17, Completed, Presage Biosciences | Recruiting --> Completed | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Feb 2025 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • tilatamig samrotecan (AZD9592) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    1m
    D9803C00001: A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cancers of the stomach and esophagus. (2024-519787-40-00)
    P2/3, N=126, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb) • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    2ms
    Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Presage Biosciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • tilatamig samrotecan (AZD9592) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    2ms
    MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)
    P1, N=175, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Jul 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)
    2ms
    GEMINI-PeriOp GC: A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=100, Recruiting, AstraZeneca
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • HER-2 negative • CLDN18.2 positive • CLDN18.2 positive + HER-2 negative
    |
    docetaxel • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    2ms
    D6187C00001: A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-small cell lung cancer (NSCLC) (2025-524843-11-00)
    P1/2, N=20, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Cyramza (ramucirumab) • rilvegostomig (AZD2936)
    3ms
    DESTINY-Lung03: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (clinicaltrials.gov)
    P1, N=304, Recruiting, AstraZeneca | N=33 --> 304
    Enrollment change • IO biomarker
    |
    HER-2 overexpression
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    3ms
    A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=1100, Recruiting, AstraZeneca | N=232 --> 1100
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    3ms
    ALTAIR: A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=152, Recruiting, AstraZeneca | N=56 --> 152
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed • rilvegostomig (AZD2936)
    3ms
    GEMINI-PeriOp GC: A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=100, Recruiting, AstraZeneca
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • HER-2 negative • CLDN18.2 positive • CLDN18.2 positive + HER-2 negative
    |
    docetaxel • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)